HCPCS Level II · Drugs administered other than oral method
J1303Injection, ravulizumab-cwvz, 10 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1303
J1303 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, ravulizumab-cwvz, 10 mg.
It was added to HCPCS effective 10/01/2019.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj., ravulizumab-cwvz 10 mg
- Date added
- 10/01/2019
- Action effective
- 10/01/2019
- BETOS
- O1E
Related J13xx codes
- J1301Injection, edaravone, 1 mg
- J1302Injection, sutimlimab-jome, 10 mg
- J1304Injection, tofersen, 1 mg
- J1305Injection, evinacumab-dgnb, 5mg
- J1306Injection, inclisiran, 1 mg
- J1307Injection, crovalimab-akkz, 10 mg
- J1308Injection, famotidine, 0.25 mg
- J1320Injection, amitriptyline hcl, up to 20 mg
- J1322Injection, elosulfase alfa, 1 mg
- J1323Injection, elranatamab-bcmm, 1 mg
- J1324Injection, enfuvirtide, 1 mg
- J1325Injection, epoprostenol, 0.5 mg
Common questions about J1303
Is HCPCS J1303 still valid?
- Yes. J1303 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J1303?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.